Towards cell therapy of polycystic ovary syndrome (pcos): human mesenchymal stem cells secretome inhibits androgen production by pcos theca cells

Conclusion Material and MethodsTheca cells, collected from normal cycling and PCOS patient underwent ovariectomy, were seeded on culture dishes pre-coated with the extracellular matrix at a density of 6 × 104 cells/ml and cultured for 24 hours. Cells were then treated with either 3T3 conditioned media as a control (C) or Mesenchymal stem cells conditioned media (CM). The C and CM were prepared through collecting the serum-free supernatant of 3T3 and hMSCs at an optimal confluence, 48 hours later. The mRNA and protein expression of CYP17A1, CYP11A1, and DENND1A.V2 were quantified by RT-PCR and Western blot, while testosterone level in media was measured by RIA assay.ResultsHuman PCOS theca cells treated with hMSCs CM for 48 hours secreted significantly lower level of testosterone (146 ± 13.6 ng/dl) compared to control C (215 ± 11.3 ng/dl) (P<0.05). The expression of CYP17A1 was decreased significantly (P<0.005) and correlate with CYP11A1 (p= 0.05) and DENND1A expression (p<0.005) in CM-treated PCOS theca cells versus control. We also confirmed our results at the protein level by western-blot analysis which revealed that CYP17A1 and DENND1A.V2 were decreased significantly under hMSCs secretome treatment (p<0.05).ConclusionThe therapeutic capabilities of hMSCs in PCOS are partially mediated by its secretome which contains various growth factors and anti-inflammatory cytokines both free and within extracellular vesicles. Stem cell therapy, either by cell im...
Source: Cytotherapy - Category: Cytology Source Type: research